Recombinant Geolycosa sp. Purotoxin-1

What is the amino acid sequence and structural characteristics of Purotoxin-1?

Purotoxin-1 is a 35-residue peptide with the sequence GYCAEKGIRC DDIHCCTGLK CKCNASGYNC VCRKK. Its structure features four disulfide bonds formed between Cys3-Cys16, Cys10-Cys21, Cys15-Cys32, and Cys23-Cys30 . Three of these disulfide bonds form an inhibitor cystine knot (ICK) motif, a structural feature common in many spider venom peptides . The molecular weight of PT1 is 3836.5 Da with a chemical composition of C₁₅₅H₂₄₈N₅₀O₄₈S₈ . Unlike many spider peptide toxins that adopt an ICK motif, PT1's specific arrangement of disulfide bonds contributes to its unique pharmacological properties and selectivity for P2X3 receptors.

How stable is Purotoxin-1 under different storage conditions and what are recommended handling protocols?

Recombinant Purotoxin-1 should be stored at -20°C, and for extended storage, it is recommended to conserve it at -20°C or -80°C . Repeated freezing and thawing should be avoided to maintain stability and activity . For working solutions, aliquots can be stored at 4°C for up to one week . The shelf life is approximately 6 months for liquid forms and 12 months for lyophilized forms when stored at -20°C/-80°C .

For reconstitution, the protein should be dissolved in deionized sterile water to a concentration of 0.1-1.0 mg/mL, with the addition of 5-50% glycerol (final concentration) for long-term storage . Prior to opening, vials should be briefly centrifuged to bring contents to the bottom . The solubility of PT1 in water is reported to be 0.1 mM . These handling protocols are critical for maintaining the structural integrity and biological activity of the peptide during experimental procedures.

What is the mechanism of action of Purotoxin-1 on P2X3 receptors?

Purotoxin-1 exhibits a complex pharmacological mechanism on P2X3 purinergic receptors. Rather than simply blocking the channel, PT1 modulates receptor function through concentration-dependent prolongation of channel desensitization, with an IC₅₀ of approximately 12 nM . This mechanism differs from conventional channel blockers, as PT1 alters the kinetics of channel recovery from the desensitized state rather than directly occluding the ion conduction pathway.

The interaction likely involves conformational changes in the receptor that stabilize the desensitized state, effectively reducing the frequency of channel activation during repeated ATP exposure. This unique mode of action may explain PT1's selective effect on pain transmission without disrupting normal physiological ATP signaling. The detailed molecular interactions between PT1 and specific domains of the P2X3 receptor remain an active area of research, particularly regarding how the ICK scaffold of PT1 contributes to its selectivity and potency.

How does Purotoxin-1 compare with other known modulators of P2X receptors in terms of selectivity and potency?

Purotoxin-1 stands out among P2X receptor modulators for its high selectivity for the P2X3 subtype. While many existing P2X modulators like suramin and PPADS exhibit broader activity across multiple P2X subtypes, PT1 demonstrates remarkable specificity for P2X3 receptors . This selectivity is particularly valuable since P2X3, P2X4, and P2X7 are all implicated in various pain states, but targeting P2X3 specifically allows for pain modulation without affecting other purinergic signaling pathways .

With an IC₅₀ of approximately 12 nM, PT1 is among the most potent known selective modulators of P2X3 . This high potency, combined with its unique mechanism of action involving prolongation of channel desensitization rather than direct channel blockade, distinguishes PT1 from traditional P2X antagonists. The selective targeting of P2X3 by PT1 makes it a valuable tool for studying pain mechanisms specifically related to this receptor subtype, which is involved in acute pain, inflammatory pain, chronic neuropathic pain, visceral pain, migraine pain, and cancer pain .

What are the optimal protocols for studying Purotoxin-1 in electrophysiological experiments?

When conducting electrophysiological studies with Purotoxin-1, researchers should consider the following methodological approach:

Preparation: Reconstitute PT1 to a stock concentration of 0.1-1.0 mg/mL in deionized water. For patch-clamp experiments, prepare working solutions in appropriate physiological buffers (e.g., standard extracellular solution for mammalian cells) immediately before use.

Cell Models: Heterologous expression systems such as HEK293 cells transfected with human P2X3 receptors provide a controlled environment for studying PT1 effects. Primary dorsal root ganglion (DRG) neurons can be used to examine effects on native P2X3 receptors.

Protocol Design: Due to PT1's mechanism involving prolongation of desensitization, design protocols that include:

• Baseline recordings with ATP application (typically 10-30 μM)

• Preincubation with PT1 (1-100 nM range) for 2-5 minutes

• Repeated ATP applications to observe changes in desensitization kinetics

Analysis: Measure multiple parameters including:

• Peak current amplitude

• Desensitization time constants (τ)

• Recovery time from desensitization

• Concentration-response relationships

Critical considerations include maintaining consistent intervals between ATP applications (typically 2-5 minutes) to allow full recovery from desensitization in control conditions, and using sufficiently long recording periods to capture the prolonged desensitization induced by PT1. Temperature control (typically 22-24°C) is also crucial as temperature affects channel kinetics.

What methodologies are recommended for assessing the analgesic properties of Purotoxin-1 in animal models?

To evaluate the analgesic potential of Purotoxin-1 in animal models, researchers should implement comprehensive testing protocols that address various pain modalities:

Preparation and Administration:

• Reconstitute PT1 in physiological saline or appropriate vehicle

• Establish dose ranges based on IC₅₀ values (~12 nM) from in vitro studies

• Consider multiple administration routes (intravenous, intrathecal, local injection) to determine optimal delivery method

Pain Models Selection:

• Acute Nociceptive Pain:

  • Hot plate or tail-flick tests for thermal nociception

  • Von Frey filament testing for mechanical sensitivity

  • Formalin test for chemical nociception (biphasic response)

• Inflammatory Pain:

  • Complete Freund's adjuvant (CFA) or carrageenan-induced inflammation

  • Measurement of hyperalgesia and allodynia using thermal and mechanical stimuli

• Neuropathic Pain:

  • Chronic constriction injury (CCI) or spared nerve injury (SNI) models

  • Assessment of mechanical and cold allodynia

• Visceral Pain:

  • Colorectal distension or acetic acid-induced writhing

  • Bladder inflammation models

Assessment Parameters:

• Behavioral responses (withdrawal latencies, thresholds)

• Motor function tests to exclude non-specific effects (rotarod, open field)

• Electrophysiological recordings from sensory neurons

• Ex vivo preparations (skin-nerve, spinal cord slice)

Control experiments should include dose-response relationships, comparison with known analgesics, and antagonist studies to confirm P2X3-specific mechanisms. Time-course studies are essential to determine onset and duration of effects. Researchers should also collect tissue samples for histological and molecular analysis to correlate behavioral outcomes with changes in P2X3 expression and signaling pathways.

How can Purotoxin-1 be used as a tool for investigating the role of P2X3 receptors in different pain states?

Purotoxin-1 offers unique advantages as a research tool for dissecting the specific contributions of P2X3 receptors in various pain conditions due to its high selectivity and unique mechanism of action. Implementing PT1 in pain research requires sophisticated experimental approaches:

For Inflammatory Pain Studies:
Researchers can administer PT1 at different time points relative to inflammatory stimuli (e.g., CFA, carrageenan) to determine whether P2X3 is involved primarily in initiation or maintenance of inflammatory hyperalgesia. Combined electrophysiological recording and calcium imaging from DRG neurons isolated from inflamed animals before and after PT1 application can reveal changes in P2X3 function during inflammation. Microdialysis combined with PT1 administration can measure changes in ATP release at peripheral injury sites and dorsal horn.

For Neuropathic Pain Investigation:
In models such as chronic constriction injury or spared nerve injury, PT1 can be administered at different stages of neuropathy development to assess temporal involvement of P2X3. Comparing PT1 efficacy in mechanical, thermal, and cold allodynia can reveal modality-specific roles of P2X3. Combining PT1 with modulators of other targets (e.g., TRPV1, Nav1.7) can reveal pathway interactions and potential for combination therapies.

For Migraine and Visceral Pain:
In models of cortical spreading depression or meningeal irritation, PT1 can help determine P2X3 involvement in migraine pathophysiology. For visceral pain, PT1 administration during colorectal distension or bladder inflammation can assess P2X3 contributions to visceral hypersensitivity. Ex vivo studies of nodose ganglion neurons treated with PT1 can reveal P2X3 roles in vagal afferent sensitization.

Molecular Signaling Studies:
PT1 can be used in conjunction with genetic approaches (conditional knockouts, optogenetics) to develop pathway maps of P2X3 signaling in different pain states. Tissue-specific administration (intrathecal vs. intraplantar) helps distinguish central vs. peripheral P2X3 contributions. Combining PT1 with inhibitors of downstream signaling (MAPK/ERK, PKC, calcium signaling) can elucidate the molecular cascade following P2X3 activation.

What are the current challenges and methodological approaches in developing structure-activity relationships for Purotoxin-1 analogs?

Developing structure-activity relationships (SAR) for Purotoxin-1 analogs presents several technical challenges that require sophisticated methodological approaches:

Structural Complexity Challenges:
The presence of four disulfide bonds (Cys3-Cys16, Cys10-Cys21, Cys15-Cys32, and Cys23-Cys30) creates significant synthetic hurdles. The ICK motif requires precise disulfide pairing for proper folding and activity. Researchers must employ regioselective disulfide bond formation strategies using orthogonal protecting groups for cysteine residues to ensure correct folding.

Methodological Approaches for SAR Development:

• Alanine Scanning and Truncation Analysis:

  • Systematic replacement of non-cysteine residues with alanine

  • N-terminal and C-terminal truncations to identify essential regions

  • Analysis of each variant's effect on P2X3 modulation by electrophysiology

• Disulfide Bond Engineering:

  • Selective replacement of disulfide pairs with diselenide bonds

  • Creation of cyclic peptide analogs with reduced number of disulfides

  • Incorporation of non-natural amino acids to stabilize secondary structure

• Pharmacophore Mapping Techniques:

  • NMR spectroscopy to determine solution structure of active analogs

  • Computational docking with homology models of P2X3 receptors

  • Molecular dynamics simulations to identify key interaction residues

  • Activity correlations with physicochemical properties (hydrophobicity, charge)

• Functional Screening Cascade:

  • High-throughput fluorescence-based assays for initial screening

  • Secondary validation using automated patch-clamp

  • Tertiary confirmation with manual patch-clamp electrophysiology

  • In vivo testing of promising candidates in pain models

A significant challenge is maintaining the balance between enhancing properties (stability, selectivity, potency) while preserving the unique mechanism of action involving desensitization modulation rather than simple channel blockade. Researchers should implement parallel synthesis strategies of multiple analogs simultaneously, followed by careful characterization of each analog's folding using circular dichroism and mass spectrometry to confirm proper disulfide formation before functional testing.

How does Purotoxin-1 compare structurally and functionally with other spider venom peptides used in pain research?

Purotoxin-1 exhibits distinct structural and functional characteristics when compared to other spider venom peptides that have applications in pain research:

Structural Comparison:
Purotoxin-1 is a 35-residue peptide with four disulfide bonds, three of which form an ICK motif . This contrasts with peptides like β-TRTX-Tp1a (also 35 residues) and β-TRTX-Tp2a (30 residues) from Thrixopelma pruriens, which target voltage-gated sodium channels and have an ICK scaffold but display different disulfide patterns . The table below summarizes these structural comparisons:

The table below compares IC₅₀ values (nM) of selected spider toxins against various targets:

Analgesic Properties Comparison:
While PT1 has demonstrated analgesic effects in rat models , its therapeutic window differs from other spider toxins. For example, β-TRTX-Tp2a is lethal to rats when injected intravenously at 1.0 mg/kg or by intrathecal administration at 0.1 mg/kg, whereas β-TRTX-Gr1b (89% identical to β-TRTX-Tp2a) induced analgesia without side effects . This highlights the importance of toxin selectivity profiles in determining therapeutic potential.

The unique selectivity of PT1 for P2X3 receptors makes it particularly valuable for studying purinergic signaling in pain, whereas other spider toxins primarily target voltage-gated channels, providing complementary approaches to pain research.

What insights can be gained from comparing the effects of Purotoxin-1 with anticancer peptides derived from spider venoms?

Comparative analysis of Purotoxin-1 with anticancer spider venom peptides reveals important insights into peptide structure-function relationships and potential dual therapeutic applications:

Mechanistic Divergence and Convergence:
Purotoxin-1 primarily functions as a P2X3 receptor modulator through prolongation of channel desensitization , whereas anticancer spider peptides like those from Macrothele raveni operate through different mechanisms, including inhibition of cell proliferation, induction of apoptosis, and cell cycle arrest . Despite these different primary targets, there are intriguing mechanistic convergences. For instance, some anticancer spider peptides like gomesin can generate reactive oxygen species (ROS) and activate signaling pathways including MAPK/ERK, PKC, and PI3K , which are also implicated in pain signaling cascades.

Structural Characteristics Comparison:
While PT1 features an ICK motif with four disulfide bonds , anticancer peptides show structural diversity. Some, like JZTX-III from Chilobrachy jingzhao, utilize the common ICK motif , whereas others like lycosin-I from Lycosa singorensis exhibit a linear amphipathic α-helical conformation . This structural diversity offers valuable insights for peptide engineering approaches.

Comparative Properties:

Translational Research Opportunities:
Comparing PT1 with anticancer peptides suggests potential unexplored activities. For example, the ability of some anticancer spider peptides to modulate calcium entry and signaling pathways points to possible broader neuromodulatory effects beyond their established anticancer properties. Similarly, PT1's selectivity for P2X3 receptors might have unexplored implications for cancer pain or even direct antitumor effects, given the emerging understanding of purinergic signaling in cancer.

A particularly noteworthy comparative insight comes from studying peptides like gomesin, which demonstrate selectivity between tumor cells and normal cells (cytotoxic to SH-SY5Y and PC12 tumor cells but minimal lytic activity on human erythrocytes) . This selective cytotoxicity principle could inform approaches to enhance PT1's therapeutic window for pain applications.

What are common technical challenges in working with recombinant Purotoxin-1 and how can they be addressed?

Researchers working with recombinant Purotoxin-1 often encounter several technical challenges that can impact experimental outcomes. Below are common issues and methodological solutions:

Challenge: Incorrect Disulfide Bond Formation
The presence of four disulfide bonds in PT1 (Cys3-Cys16, Cys10-Cys21, Cys15-Cys32, and Cys23-Cys30) creates a significant challenge for proper folding of recombinant protein.

Solution:

• Implement oxidative folding under controlled conditions (e.g., glutathione redox buffer systems)

• Verify correct disulfide pairing using mass spectrometry and partial reduction/alkylation techniques

• Consider expressing PT1 with fusion partners like thioredoxin that facilitate correct disulfide formation

• Optimize folding conditions by screening various pH values (7.5-8.5), temperatures (4°C vs. room temperature), and redox ratios

Challenge: Protein Aggregation During Storage
Recombinant PT1 may form aggregates during freeze-thaw cycles or extended storage.

Solution:

• Add 5-50% glycerol to storage buffer as recommended

• Prepare single-use aliquots to avoid repeated freeze-thaw cycles

• Filter solutions through 0.22 μm filters before storage

• Monitor aggregation using dynamic light scattering or size-exclusion chromatography

• For working solutions, store at 4°C for no more than one week

Challenge: Variable Activity in Functional Assays
Inconsistency in electrophysiological responses or biological activity.

Solution:

• Implement bioactivity assays after each preparation to confirm functionality

• Use positive controls with known P2X3 modulators in parallel experiments

• Standardize protein concentration determination methods (e.g., BCA assay with BSA standard curve)

• Prepare fresh working solutions for each experiment

• Validate activity using multiple techniques (electrophysiology, calcium imaging, binding assays)

Challenge: Low Expression Yields in Recombinant Systems
Difficulty obtaining sufficient quantities of functional protein.

Solution:

• Optimize codon usage for expression system (yeast , E. coli, or mammalian cells)

• Consider using secretion signal sequences for extracellular expression

• Test different fusion tags (His, GST, MBP) for improved solubility

• Implement auto-induction media for bacterial expression

• Explore insect cell expression systems for complex disulfide-rich proteins

Challenge: Interference from Contaminants
Buffer components or contaminants affecting experimental outcomes.

Solution:

• Ensure high purity (>85% by SDS-PAGE or >99% by HPLC )

• Implement rigorous purification protocols (multiple chromatography steps)

• Dialyze thoroughly against appropriate buffers before experiments

• Consider control experiments with heat-denatured PT1 to identify non-specific effects

• Test for endotoxin contamination if using in cell culture or in vivo experiments

What are the critical parameters to consider when designing experiments to study the specificity of Purotoxin-1 for P2X3 versus other purinergic receptors?

When investigating the specificity of Purotoxin-1 for P2X3 versus other purinergic receptors, researchers must carefully design experiments that account for several critical parameters:

Expression System Selection:
The choice of cellular model significantly impacts receptor pharmacology. Use heterologous expression systems (HEK293, Xenopus oocytes) expressing single P2X receptor subtypes (P2X1-7) for direct comparison. For physiological relevance, complement with native systems expressing multiple P2X subtypes, such as:

• Dorsal root ganglion neurons (P2X3, P2X2/3)

• Nodose ganglion neurons (P2X2/3)

• Microglia (P2X4, P2X7)

• Smooth muscle cells (P2X1)

Implement molecular approaches to manipulate receptor expression:

• siRNA knockdown of specific subtypes

• CRISPR/Cas9 knockout cell lines

• Selective overexpression of individual receptor subtypes

Pharmacological Discrimination Strategy:
Design protocols that can distinguish between effects on different receptor subtypes:

• Subtype-Selective Agonist Profiling:

  • α,β-meATP (P2X1, P2X3-selective)

  • 2-meSATP (broader spectrum)

  • BzATP (potent at P2X7)
    Apply PT1 and measure inhibition profiles across agonists

• Antagonist Competitive Studies:

  • Co-apply PT1 with known subtype-specific antagonists:

    • TNP-ATP (P2X1, P2X3)

    • A-317491 (P2X3-selective)

    • 5-BDBD (P2X4-selective)

    • A-438079 (P2X7-selective)

  • Analyze competitive, additive, or synergistic effects

• Desensitization Kinetics Analysis:

  • P2X3 receptors show rapid desensitization

  • P2X7 shows pore dilation rather than desensitization

  • Measure PT1 effects on:

    • Rate of desensitization (τfast, τslow)

    • Recovery from desensitization

    • Current amplitude during repeated applications

Biophysical and Biochemical Characterization:
Implement multiple complementary techniques:

• Binding Assays:

  • Radiolabeled PT1 binding to membrane preparations

  • Fluorescently-labeled PT1 for fluorescence correlation spectroscopy

  • Surface plasmon resonance with purified receptor ectodomains

• Mutagenesis Studies:

  • Chimeric receptors (P2X3/P2X2 or P2X3/P2X4)

  • Point mutations at potential interaction sites

  • Deletion constructs to identify binding domains

• Structural Biology Approaches:

  • Computational docking of PT1 to homology models of P2X receptors

  • Crosslinking studies to identify interaction sites

  • Hydrogen-deuterium exchange mass spectrometry

Control Parameters and Validation:
Implement rigorous controls including:

• Concentration-response curves (1-1000 nM range)

• Time controls for desensitization

• Vehicle controls for all solvents used

• Positive controls using known modulators

• Testing heat-denatured PT1 to control for non-specific effects

By systematically addressing these parameters, researchers can comprehensively characterize PT1's selectivity profile and identify the structural determinants of its specificity for P2X3 receptors, potentially leading to the development of improved analgesic compounds with enhanced selectivity profiles.

What are emerging approaches for optimizing the therapeutic potential of Purotoxin-1 for pain management?

Several innovative approaches are being explored to enhance the therapeutic potential of Purotoxin-1 for pain management:

Peptide Engineering Strategies:
Building on PT1's natural selectivity for P2X3 receptors, researchers are exploring structure-based modifications to enhance therapeutic properties. These include:

• Cyclization techniques to improve stability while maintaining the critical ICK motif

• Non-natural amino acid incorporation to enhance protease resistance

• Minimal pharmacophore identification to develop smaller, more bioavailable analogs

• PEGylation or fusion to albumin-binding domains to extend half-life

These modifications must carefully preserve the unique mechanism involving prolongation of P2X3 desensitization rather than simple channel blockade , which may be responsible for PT1's favorable therapeutic profile.

Novel Delivery Approaches:
The peptidic nature of PT1 presents delivery challenges that can be addressed through:

• Encapsulation in nanoparticles for controlled release and protection from degradation

• Cell-penetrating peptide conjugation for enhanced membrane permeability

• Targeted delivery systems using pain neuron-specific ligands

• Local delivery formulations (hydrogels, patches) for peripheral application

• Route optimization (peripheral vs. intrathecal vs. intraganglion) based on P2X3 expression patterns in different pain states

Combined Modality Approaches:
Synergistic combinations with other pain therapeutics show promise:

• Co-administration with Nav1.7 blockers like β-TRTX-Tp2a for multimodal pain inhibition

• Combination with low-dose opioids to reduce opioid requirements and tolerance development

• Integration with TRPV1 modulators for comprehensive nociceptor silencing

• Exploration of PT1 effects on microglia and neuroinflammation as additive mechanisms

Genetic and Cell-Based Therapies:
Advanced approaches leveraging PT1's mechanism include:

• Viral vector delivery of engineered PT1 genes under pain-specific promoters

• CRISPR-based approaches to modify P2X3 receptor properties to mimic PT1 effects

• Cell-based delivery using engineered stem cells that secrete optimized PT1 variants

• Optogenetic or chemogenetic systems to control PT1 release in response to pain signals

These approaches are being evaluated with emphasis on:

• Enhanced specificity for particular pain types (inflammatory vs. neuropathic)

• Minimized side effects through targeted delivery

• Improved pharmacokinetic profiles compared to native PT1

• Development of biomarkers to identify patients most likely to respond to PT1-based therapies

The optimization of PT1 for therapeutic applications represents a compelling approach to address the critical need for non-opioid pain management solutions with improved safety profiles.

How might systems biology approaches advance our understanding of Purotoxin-1's effect on pain signaling networks?

Systems biology offers powerful frameworks to unravel the complex effects of Purotoxin-1 beyond its direct action on P2X3 receptors, providing a holistic understanding of its impact on pain signaling networks:

Multi-Omics Integration Methodologies:
Combining multiple layers of biological information can reveal PT1's comprehensive effects:

• Transcriptomics:

  • RNA-seq analysis of DRG neurons before and after PT1 treatment

  • Single-cell transcriptomics to identify cell type-specific responses

  • Temporal expression profiling to track adaptive changes following chronic PT1 exposure

• Proteomics and Post-Translational Modifications:

  • Global proteome analysis to identify changes beyond immediate P2X3 targets

  • Phosphoproteomics to map signaling cascade alterations

  • Analysis of membrane protein trafficking and surface expression changes

• Metabolomics:

  • Profiling ATP and related purine metabolites in pain circuits

  • Examining lipid mediator changes that may contribute to analgesic effects

  • Correlation of neurotransmitter metabolism with behavioral outcomes

Network Pharmacology Approaches:
Computational methods can map the broader impact of PT1 on cellular networks:

• Protein-Protein Interaction Mapping:

  • Identification of P2X3 interactome alterations following PT1 binding

  • Network perturbation analysis to identify key nodes and potential secondary targets

  • Prediction of functional consequences using network topology analysis

• Signaling Pathway Modeling:

  • Differential equation-based models of calcium signaling affected by PT1

  • Agent-based models of neuronal excitability incorporating P2X3 kinetics

  • Identification of feedback loops and compensatory mechanisms

• Multi-Scale Integration:

  • Linking molecular events to cellular physiology and ultimately behavior

  • Incorporating temporal dynamics from immediate effects to long-term adaptations

  • Identifying emergent properties not predictable from single-target analysis

Translational Systems Approaches:
Bridging preclinical findings to clinical applications:

• Patient Stratification Models:

  • Identification of biomarkers predicting PT1 responsiveness

  • Integration of genetic, epigenetic, and clinical variables

  • Development of companion diagnostics for precision pain medicine

• Disease Network Comparisons:

  • Comparing PT1 effects across different pain conditions

  • Identifying condition-specific and shared mechanisms

  • Mapping drug-disease networks to identify repurposing opportunities

• Predictive Pharmacology:

  • In silico prediction of PT1 analog efficacy profiles

  • Virtual screening for synergistic combination therapies

  • Modeling of side effect mechanisms and mitigation strategies

Implementation of these systems biology approaches requires interdisciplinary collaboration and sophisticated data integration platforms. The resulting comprehensive understanding of PT1's effects would not only advance its therapeutic development but also contribute to fundamental pain neurobiology knowledge by revealing how perturbation of a single target (P2X3) propagates through interconnected signaling networks to ultimately modulate the complex experience of pain.